GPC Biotech news from FierceBiotech
NewsReport: Wilex, GPC nearing merger pact
Two German biotech companies which share a very big investor are preparing to merge, according to a prominent German newspaper. Wilex and GPC Biotech, both involved in developing new cancer Read more...
GPC jettisons 38 workers in new round of layoffs
GPC Biotech's failure to get an FDA approval on satraplatin for cancer will cost the jobs of another Read more...
ALSO NOTED: GPC Biotech's CFO resigns; Abbott Labs cuts 1,200 jobs; and much more...
> GPC Biotech's CFO Mirko Scherer has resigned; he will be replaced by Torsten Hombeck, Ph.D. Read more...
Struggling GPC looking for merger or acquisition
Wanted: Private drug developer interested in partnering with struggling biotech specializing in cancer therapies. GPC Biotech essentially posted that message when its CEO announced that he is Read more...
GPC Biotech reports Q3 results, layoffs
GPC Biotech is regrouping after last week's announcement Read more...
GPC shares crater on Phase III cancer failure
Germany's GPC Biotech saw its already battered stock price crater this morning after announcing that its experimental prostate cancer drug, satraplatin, failed to help patients live longer in a Read more...
FDA delay forces cutbacks at GPC Biotech
Struggling to overcome FDA hurdles for its cancer drug satraplatin, Germany's GPC Biotech says it will slash its staff by 15 Read more...
SPOTLIGHT: GPC hit by high R&D costs
Germany's GPC Biotech announced wider losses as a result of the expense of developing its prostate cancer therapy Satraplatin. A recent delay in gaining FDA approval of the drug sent GPC shares Read more...
Industry exec says FDA approval process too strict
Citing the recent decision by GPC Biotech to withdraw its application for satraplatin, Pharmacyclics Read more...
| Press ReleasesPRESS RELEASE: GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer GPC Biotech Appoints Torsten Hombeck as Chief Financial Officer Martinsried/Munich (Germany) and Princeton, N.J., December 4, 2007 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; Read more... PRESS RELEASE: GPC Biotech Announces Corporate Restructuring GPC Biotech Announces Corporate Restructuring Martinsried/Munich (Germany) and Princeton, N.J., November 15, 2007 – GPC Biotech AG (Frankfurt Stock Exchange: GPC; TecDAX index; NASDAQ: GPCB) today Read more... PRESS RELEASE: November 8, 2007 GPC Biotech Reports Financial Results for Third Quarter and First Nine Months of 2007 November 8, 2007 GPC Biotech Reports Financial Results for Third Quarter and First Nine Months of 2007 • Year-end 2007 cash, cash equivalents and available-for-sale securities position expected to Read more... PRESS RELEASE: GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial GPC Biotech and Pharmion Announce Results of Overall Survival Analysis from the Satraplatin Pivotal Phase 3 Trial • Overall survival results do not achieve statistical significance • GPC Biotech Read more... |
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets